
    
      A Phase I study is designed to assess the PK, safety and tolerability of single-dose and
      multiple-dose capivasertib as monotherapy (Part A) and in combination with paclitaxel (Part
      B) in approximately 16 Chinese participants with advanced solid tumours and to detect any
      differences in the PK profile between Chinese and Caucasian participants due to ethnicity.
      Descriptive summary will be conducted on the PK analysis set and safety analysis set.The
      evaluation of capivasertib PK data will be based on the PK analysis set.The assessment on
      safety and tolerability will be based on the safety analysis set.
    
  